IL1RAP and cancer: Using the multi-cancer optimization approach, ENPP1 and CDH11, validated novel targets by Mooney and colleagues, scored in the top 2% of targets (Fig. 5A) and using the phenotype-specific prioritization parameters, IL1RAP, a previously validated target within EwS, ENPP1, and CDH11 scored as the top three targets (Fig. 5B; Supplementary Tables S5 and S6).